The global prevalence of type 2 diabetes mellitus (T2DM) continues to rise, with over 140 million patients in China alone. Disease management faces challenges such as insufficient blood glucose control rates and a heavy burden of complications. Traditional treatment models are gradually transitioning toward a multidimensional management approach focusing on blood glucose, weight, and cardiovascular health. In this context, tirzepatide, as the world's first GIP/GLP-1 dual receptor agonist, is reshaping the landscape of diabetes treatment with its innovative mechanism and significant clinical benefits.
|
|
1.General Specification(in stock) |
Innovative mechanism
|
Dual activation of GIP/GLP-1 receptors Tirperptide achieves multiple metabolic regulation by simultaneously binding to GIP and GLP-1 receptors: 1) GLP-1 pathway: Promotes insulin secretion in a glucose-dependent manner, inhibits glucagon release, delays gastric emptying by 40%-60%, and increases satiety. 2) GIP pathway: Enhances insulin sensitivity in adipose tissue, promotes postprandial lipid storage in white fat, and reduces ectopic fat deposition by over 30%. Preclinical studies indicate that dual receptor activation produces synergistic effects: in a diabetic mouse model, tirzepatide's efficacy in lowering blood glucose was 2.3 times greater than that of a single-target agonist, and its weight-loss effect was 1.8 times greater. |
|
|
|
Metabolic Regulation Network Analysis Tirperotide regulates metabolism through dual central-peripheral pathways: 1) Central Nervous System: Acts on the hypothalamic arcuate nucleus to reduce neuropeptide Y (NPY) expression, decreasing energy intake by 15–20%. 2) Peripheral tissues: It increases skeletal muscle glucose uptake by 25%, inhibits hepatic glucose output by 40%, and improves adipose tissue function. This multi-level regulatory mechanism enables it to achieve significant weight loss and metabolic improvement while lowering blood glucose levels. Basic research has confirmed that telbopride can upregulate GLUT4 expression in adipocytes and enhance insulin signaling. |
The Efficacy of Tirzepatide in the Treatment of Type 2 Diabetes
(1) Significant Hypoglycemic Effects
Multiple clinical trials have confirmed the outstanding hypoglycemic effects of tirzepatide in the treatment of type 2 diabetes. In the SURPASS series of studies, tirzepatide demonstrated a powerful ability to lower glycated hemoglobin (HbA1c). For example, in the SURPASS-1 study, 92% of tirzepatide participants had HbA1c levels below 7%; over 52% of patients had HbA1c levels below 5.7%, while only 1% of placebo recipients achieved this level. This indicates that tirzepatide can significantly improve patients' glycemic control, enabling more patients to achieve optimal glycemic targets.
(2) Superior weight-loss effects
In addition to lowering blood sugar, tirzepatide also demonstrates outstanding weight-loss effects. Obesity is a major risk factor for type 2 diabetes, and weight loss is crucial for improving blood glucose control and reducing cardiovascular risk. In the SURMOUNT-1 study, patients treated with 15 mg of tirzepatide achieved an average weight loss of 22.9%, while the placebo group only lost 2.1%. The SURMOUNT-CN study conducted in the Chinese population also demonstrated that tirzepatide helped patients achieve significant weight loss over 52 weeks, with an average weight loss of 11.3% to 15.1%. Over 85% of patients achieved significant weight loss, with a weight loss rate of 85.8% to 87.7%. This superior weight loss effect gives tirzepatide a unique advantage in the treatment of type 2 diabetes.
(3) Improving insulin sensitivity
Long-term use of tirzepatide significantly enhances insulin sensitivity and effectively reduces insulin resistance. In a key study, 117 patients with type 2 diabetes were randomly assigned to three groups, receiving tirzepatide 15 mg, semaglutide 1 mg, or placebo, respectively. Insulin sensitivity was assessed using a high-insulin euglycemic clamp test. At the end of the 28-week study, both the tirzepatide and semaglutide groups showed an increase in glucose infusion rate, with the tirzepatide group exhibiting a significantly higher glucose infusion rate than the semaglutide group. This suggests that tirzepatide can effectively enhance insulin sensitivity, reduce insulin resistance, and help the body respond more naturally to insulin, thereby more effectively controlling blood glucose levels.
(4) Cardiovascular protective effects
Patients with type 2 diabetes have a significantly increased risk of cardiovascular disease, so the cardiovascular protective effects of antidiabetic drugs are of great concern. The SURPASS-CVOT study is the first global large-scale head-to-head study comparing the cardiovascular outcomes of two incretin-based drugs, comparing tirzepatide with the GLP-1 receptor agonist dulaglutide, which has cardiovascular protective effects. The study results showed that tirzepatide was non-inferior to dulaglutide in terms of the risk of major adverse cardiovascular events (MACE-3, including cardiovascular death, myocardial infarction, or stroke). Additionally, tirzepatide demonstrated improvements in A1C, weight, kidney function, and all-cause mortality. This suggests that tirzepatide not only effectively controls blood glucose and weight but also has cardiovascular protective effects, providing a more comprehensive health benefit for patients with type 2 diabetes.
From blood sugar control to organ protection
● SURPASS Series Studies: Dual Breakthroughs in Glycemic Control and Weight Loss
The global Phase III SURPASS study enrolled 12,313 patients with type 2 diabetes mellitus (T2DM) and demonstrated the significant efficacy of tirzepatide at different doses:
1) Glycemic control: The 15mg dose group achieved an average reduction in HbA1c of 2.37%, with 89% of patients reaching target levels (<7%), representing an additional 0.5% reduction compared to the semaglutide group.
Weight management: Average weight loss of 13.1%, with 46% of patients losing over 15% of their body weight, a 32% reduction in abdominal subcutaneous fat, and a 28% reduction in visceral fat.
2) Metabolic improvements: Total cholesterol decreased by 15%, triglycerides decreased by 25%, HDL-C increased by 8%, and blood pressure decreased by 5/3 mmHg.
The SURPASS-AP-Combo study conducted in China demonstrated the non-inferiority of tirzepatide in Asian populations: the 10 mg dose group achieved an HbA1c reduction of 2.40%, weight loss of 8.7 kg, and a 12% lower incidence of gastrointestinal adverse reactions compared to the global population.
● SURMOUNT-1 Study: A Milestone in Diabetes Prevention
In a three-year study targeting obese individuals with prediabetes, tirzepatide demonstrated its preventive potential:
1) Reduced progression risk: Compared with placebo, the risk of developing type 2 diabetes was reduced by 94% (HR=0.06, 95% CI: 0.02-0.19).
2) Sustained weight loss effect: The 15mg dose group experienced an average weight loss of 22.9%, with 18.2% of the weight loss maintained 17 weeks after discontinuation, and less than 3% muscle mass loss.
Improved metabolic markers: Fasting blood glucose decreased by 2.1mmol/L, insulin resistance index (HOMA-IR) reduced by 65%, and 78% of liver enzyme levels returned to normal.
SURPASS-CVOT study: Confirmation of cardiovascular protection
The first global cardiovascular outcomes study of an incretin-based drug confirmed:
Primary endpoint: Non-inferiority of MACE-3 event risk compared to dulaglutide (HR = 0.98, 95% CI: 0.86–1.12), with secondary analysis showing a 16% reduction in all-cause mortality risk.
Renal protection: Annual decline in eGFR slowed by 32%, and the incidence of proteinuria decreased by 21%, significantly delaying the progression of diabetic nephropathy.
Mechanism exploration: Improved myocardial energy metabolism, reduced atherosclerotic plaque volume by 19%, and improved vascular endothelial function score by 28%.
Conclusion
Tirperptide, as a novel dual agonist of the GIP/GLP-1 receptor, demonstrates significant potential in the treatment of type 2 diabetes due to its unique pharmacological mechanism of action and notable clinical efficacy. Its significant blood glucose-lowering and weight-reducing effects, along with improvements in insulin sensitivity and cardiovascular protection, offer type 2 diabetes patients a more comprehensive and effective treatment option.
As more clinical trials are conducted and research progresses, the indications for tirperceptide are expected to expand further, with promising therapeutic effects anticipated in conditions such as chronic kidney disease, psoriatic arthritis, obstructive sleep apnea syndrome, and liver failure. In the future, tirperceptide is poised to become one of the key drugs for treating type 2 diabetes, bringing health and hope to more patients.
However, we should also recognize that drug therapy is only part of the comprehensive management of type 2 diabetes. While using Tilapeptide, patients should also actively improve their lifestyle, including maintaining a balanced diet, engaging in moderate exercise, quitting smoking, and limiting alcohol consumption, to achieve better treatment outcomes. Additionally, doctors should develop personalized treatment plans based on the patient's specific condition to ensure the safety and efficacy of the medication.
In summary, the introduction of tirzepatide has brought a new breakthrough in the treatment of type 2 diabetes. We have every reason to believe that with the continuous progress of medical research, the treatment of type 2 diabetes will achieve even more significant advancements, safeguarding patients' health.